Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company focused on the domestic pharmaceutical manufacturing sector. On April 14, 2026, the company filed a definitive proxy statement (DEF 14A, accession 0001213900-26-043527), a filing type typically associated with a shareholder vote on a proposed business combination. DMAAR's name and sector thesis align with heightened policy and capital market interest in U.S.-based drug manufacturing and supply chain resilience. Sponsor details and IPO vintage were not disclosed in this filing. Investors tracking SPAC activity in the healthcare and pharmaceutical space can sign up for full data, filings, and deal analytics on SpacDesk.